Thyroid CancerNCT03765333
GETNE Registration of Thyroid Cancer
An observational study of Thyroid Cancer, run by Grupo Espanol de Tumores Neuroendocrinos at 1 site in Spain.
Trial summary
An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Thyroid Cancer
- How many people
- 20 participants
- Where
- 1 siteSpain
- Study dates
- 28 May 2019to Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients ≥ 18 years visited in the oncology services of the participating centers that have a diagnosis of primary cancer located in the thyroid gland.
Who may be able to join
- Patients older than 18 years with diagnosis of differentiated, medullary or anaplastic thyroid cancer confirmed by histopathology.
- Patients who agree to participate and are able to understand the information sheet and sign the informed consent
Who cannot join
- Patients under 18 years of age.
- Patients with other types of thyroid cancer or whose histopathological diagnosis has not been confirmed.
- Patients who do not have the relevant basic information to be included in the study, according to the criteria of the principal investigator.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona
A responsible person designated by the sponsor, M.D., investigacion@mfar.net
Principal investigator selected by the sponsor, M.D.
About this study
Official title: Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic
An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.
- Conditions
- Thyroid Cancer
- Medical subject headings
- Thyroid Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Hystopathological characteristics of the tumor
Based on pathologist evaluation of biopsy including differentiated, medullar or anaplasic.
Measured: Baseline
Situation of the tumor at first-diagnosis
Local tumor, locoregional tumor or metastatic disease.
Measured: Baseline
Tumor-Node-Metastasis classification
Based on the AJCC (American Joint Committee on Cancer) 2018 TNM system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Measured: Baseline
Tumor Stage
From I to IV, based on the interpretation of the TNM classification and depending on the hystopathological characteristics of the tumor.
Measured: Baseline
Secondary outcomes (8)
Patient situation at the end of treatment
Results of clinical evaluation of the disease including complete response, partial response, stable disease, progression of disease or death
Measured: 12 months
Number of patients with BRAF mutation
Total patients with available results on BRAF status and proportion of patients with mutated BRAF or native BRAF.
Measured: 12 months
Number of patients with RET mutation
Total patients with available results on RET status and proportion of patients with mutated RET or native RET.
Measured: 12 months
Number of patients with PI3K mutation
Total patients with available results on PI3K status and proportion of patients with mutated PI3K or native PI3K.
Measured: 12 months
Number of patients with RAS mutation
Total patients with available results on RAS status and proportion of patients with mutated RAS or native RAS.
Measured: 12 months
Number of patients with PAX8/PAR mutation
Total patients with available results on PAX8/PAR status and proportion of patients with mutated PAX8/PAR or native PAX8/PAR.
Measured: 12 months
Number of patients with P53 mutation
Total patients with available results on P53 status and proportion of patients with mutated P53 or native P53.
Measured: 12 months
Number of patients with PTEN mutation
Total patients with available results on PTEN status and proportion of patients with mutated PTEN or native PTEN.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2018
- Study start28 May 2019
- Primary completionDec 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thyroid CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jorge Hernando Cubero, M.D., Study director, Hospital Universitari Vall d'Hebron, BarcelonaJaume Capdevila, M.D., Study chair, Hospital Universitari Vall d'Hebron, Barcelona
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03765333
- Sponsor's protocol ID
- REGETNE-Tiroides
- Status last verified
- Sep 2026
- First submitted
- 20 Nov 2018
- Last updated
- 22 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic
- ClinicalTrials.gov ID
- NCT03765333
- Acronym / sponsor ID
- REGETNE-Tiroides
- Conditions
- Thyroid Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Grupo Espanol de Tumores NeuroendocrinosUniversity, hospital or other
- Study start
- 28 May 2019 (actual)
- Primary completion
- Dec 2028 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 5 Dec 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients ≥ 18 years visited in the oncology services of the participating centers that have a diagnosis of primary cancer located in the thyroid gland.
Key inclusion criteria (2 listed)
- Patients older than 18 years with diagnosis of differentiated, medullary or anaplastic thyroid cancer confirmed by histopathology.
- Patients who agree to participate and are able to understand the information sheet and sign the informed consent
Key exclusion criteria (3 listed)
- Patients under 18 years of age.
- Patients with other types of thyroid cancer or whose histopathological diagnosis has not been confirmed.
- Patients who do not have the relevant basic information to be included in the study, according to the criteria of the principal investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Hystopathological characteristics of the tumor
Time frame: Baseline
Based on pathologist evaluation of biopsy including differentiated, medullar or anaplasic.
Situation of the tumor at first-diagnosis
Time frame: Baseline
Local tumor, locoregional tumor or metastatic disease.
Tumor-Node-Metastasis classification
Time frame: Baseline
Based on the AJCC (American Joint Committee on Cancer) 2018 TNM system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Tumor Stage
Time frame: Baseline
From I to IV, based on the interpretation of the TNM classification and depending on the hystopathological characteristics of the tumor.
8 secondary outcomes
Patient situation at the end of treatment
Time frame: 12 months
Number of patients with BRAF mutation
Time frame: 12 months
Number of patients with RET mutation
Time frame: 12 months
Number of patients with PI3K mutation
Time frame: 12 months
Number of patients with RAS mutation
Time frame: 12 months
Number of patients with PAX8/PAR mutation
Time frame: 12 months
Number of patients with P53 mutation
Time frame: 12 months
Number of patients with PTEN mutation
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Thyroid Cancer
Recruiting
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Hypocalcemia, Hypoparathyroidism
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingObservational study
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Pleuropulmonary Blastoma, Cystic Nephroma
Recruiting
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Thyroid Gland Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jorge Hernando Cubero, M.D. study director
Hospital Universitari Vall d'Hebron, Barcelona
Jaume Capdevila, M.D. study chair
Hospital Universitari Vall d'Hebron, Barcelona
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid Cancer, run by Grupo Espanol de Tumores Neuroendocrinos at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Secretaria Técnica GETNE (+34 93 434 44 12, getne@mfar.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hystopathological characteristics of the tumor (time frame: Baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2026.